The market expects Regeneron (REGN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...
On Wednesday, Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $941.39 which represents a decrease of $-20.95 or -2.18% from the prior close of $962.34. The stock opened at ...